1. Home
  2. EWTX vs NEXT Comparison

EWTX vs NEXT Comparison

Compare EWTX & NEXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • NEXT
  • Stock Information
  • Founded
  • EWTX 2017
  • NEXT 2010
  • Country
  • EWTX United States
  • NEXT United States
  • Employees
  • EWTX N/A
  • NEXT N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • NEXT Oil & Gas Production
  • Sector
  • EWTX Health Care
  • NEXT Energy
  • Exchange
  • EWTX Nasdaq
  • NEXT Nasdaq
  • Market Cap
  • EWTX 1.6B
  • NEXT 1.8B
  • IPO Year
  • EWTX 2021
  • NEXT N/A
  • Fundamental
  • Price
  • EWTX $14.95
  • NEXT $7.44
  • Analyst Decision
  • EWTX Buy
  • NEXT Hold
  • Analyst Count
  • EWTX 10
  • NEXT 2
  • Target Price
  • EWTX $37.90
  • NEXT $9.00
  • AVG Volume (30 Days)
  • EWTX 957.0K
  • NEXT 6.2M
  • Earning Date
  • EWTX 11-06-2025
  • NEXT 11-06-2025
  • Dividend Yield
  • EWTX N/A
  • NEXT N/A
  • EPS Growth
  • EWTX N/A
  • NEXT N/A
  • EPS
  • EWTX N/A
  • NEXT N/A
  • Revenue
  • EWTX N/A
  • NEXT N/A
  • Revenue This Year
  • EWTX N/A
  • NEXT N/A
  • Revenue Next Year
  • EWTX N/A
  • NEXT N/A
  • P/E Ratio
  • EWTX N/A
  • NEXT N/A
  • Revenue Growth
  • EWTX N/A
  • NEXT N/A
  • 52 Week Low
  • EWTX $10.60
  • NEXT $4.94
  • 52 Week High
  • EWTX $38.12
  • NEXT $12.12
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 49.70
  • NEXT 43.44
  • Support Level
  • EWTX $14.85
  • NEXT $6.45
  • Resistance Level
  • EWTX $15.84
  • NEXT $7.39
  • Average True Range (ATR)
  • EWTX 1.08
  • NEXT 0.37
  • MACD
  • EWTX -0.06
  • NEXT 0.13
  • Stochastic Oscillator
  • EWTX 31.42
  • NEXT 97.02

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

Share on Social Networks: